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Background: The presence of an extra whole or part of chromosome 21 in people with Down syndrome (DS) is
associated with multiple neurological changes, including pathological aging that often meets the criteria for
Alzheimer’s Disease (AD). In addition, trisomies have been shown to disrupt normal epigenetic marks across the
genome, perhaps in response to changes in gene dosage. We hypothesized that trisomy 21 would result in global
epigenetic changes across all participants, and that DS patients with cognitive impairment would show an
additional epigenetic signature.
Methods: We therefore examined whole-genome DNA methylation in buccal epithelial cells of 10 adults with DS
and 10 controls to determine whether patterns of DNA methylation were correlated with DS and/or cognitive
impairment. In addition we examined DNA methylation at the APP gene itself, to see whether there were changes
in DNA methylation in this population. Using the Illumina Infinium 450 K Human Methylation Array, we examined
more than 485,000 CpG sites distributed across the genome in buccal epithelial cells.
Results: We found 3300 CpGs to be differentially methylated between the groups, including 495 CpGs that overlap
with clusters of differentially methylated probes. In addition, we found 5 probes that were correlated with cognitive
function including two probes in the TSC2 gene that has previously been associated with Alzheimer’s disease
pathology. We found no enrichment on chromosome 21 in either case, and targeted analysis of the APP gene
revealed weak evidence for epigenetic impacts related to the AD phenotype.
Conclusions: Overall, our results indicated that both Trisomy 21 and cognitive impairment were associated with
distinct patterns of DNA methylation.
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Down syndrome (DS) occurs in approximately 1 out of
every 600 live births in the US and is the most prevalent
genetic cause of developmental disabilities [1]. It is due
to the presence of an additional whole or partial copy of
chromosome 21 resulting in developmental changes be-
ginning early in fetal life. Clinical features of DS include
mental retardation, stereotypical facial features, poor
muscle tone, and short stature. People with DS are at* Correspondence: naznin.virji-babul@ubc.ca; msk@cmmt.ubc.ca
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reproduction in any medium, provided the orincreased risk of congenital heart disease, periodontal
disease, diabetes and leukemia, and often show acceler-
ated cognitive impairment with age [2-4].
Postmortem studies show that from the age of 40 up-
ward, individuals with DS are at much higher risk than
the general population of having neuropathological
changes that meet the clinical criteria for Alzheimer’s
Disease (AD) [5-7]. These include extensive cerebral at-
rophy, accumulation of β-amyloid, extracellular senile
plaques and intracellular neurofibrillary tangles in the
hippocampus, and frontal and temporal cortices. In
addition, functional brain imaging studies reveals spectral
slowing in the brain activity of DS subjects, particularly
in bilateral temporal regions known to be associated
with learning and memory [8]. Memory impairments aretd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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protein gene on chromosome 21 [5,6,9]. This gene is
thought to have multiple possible implications to the eti-
ology of DS which overlap with AD symptoms, including
transcriptional modulation and amyloid plaque formation
[8,10,11]. Since individuals with DS have three copies of
chromosome 21, it is suspected that an overexpression
of the amyloid precursor protein contributes to the in-
creased risk of AD in this population [7,12,13].
One mechanism by which cells may respond to
changes in gene dosage is altered DNA methylation.
DNA methylation is one of a group of epigenetic modifi-
cations to the genome which affect the ability of specific
genes to be expressed but do not modify the sequence of
the genome itself. One of the best-characterized effects
of DNA methylation is its contribution to the inactiva-
tion of one entire X chromosome in females, which re-
stores dosage equality with XY males. Methyl groups are
added to CpG dinucleotides, and these modifications in
turn recruit chromatin remodeling complexes which
alter the structure of the surrounding chromatin, either
increasing or decreasing the availability for the gene to
be expressed. Changes in DNA methylation are associated
with both normal aging and with Alzheimer’s Disease
[14-16]. Additionally, the APP promoter is specifically
hypomethylated in brain tissues from AD patients [17].
Previous studies examined leukocytes and fetal tissues of
DS participants for changes in DNA methylation using
lower-resolution genome-wide approaches, and found sig-
nificant differences in a number of genes, as did a recent
study examining DS placental tissue using reduced repre-
sentation bisulfite sequencing [18-20].
We hypothesize that altered DNA methylation on
chromosome 21 and across the genome may be associ-
ated with accelerated cognitive aging in DS. To that end,
we examined a cohort of 10 adult participants with DS
and 10 age- and sex-matched controls. We evaluated
cognitive function and collected cheek swabs from each
participant. Genome-wide DNA methylation patterns
were analyzed using the Illumina 450K Human Methyla-
tion Array, which interrogates over 480,000 CpG dinucleo-
tides in the genome, including over 4000 on Chromosome
21 itself, and were correlated with scores related to cogni-
tive function.
Methods
Participants
This study was approved by the University of British
Columbia Clinical Research Ethics Board. Participants
with DS were recruited from the Down Syndrome Re-
search Foundation (DSRF), in Burnaby, B.C. Informed
consent was provided by either a parent or guardian,
and assent was obtained from the participant. Age and
gender matched control participants were recruited fromthe staff and students at the Child and Family Research
Institute (CFRI) in Vancouver, B.C. A total of 20 adults
between the ages of 27–46 years of age, 10 with DS (5
Male, 5 Female) and 10 controls (5 Male, 5 Female) par-
ticipated in this study. All participants were financially
compensated for parking and travel costs.
Dalton brief praxis test
The Dalton Brief Praxis Test (BPT) is an abbreviated,
20-item version of the Dyspraxia Scale for Adults with
Down’s Syndrome, a 62-item cognitive test of praxis. It
scores the ability to perform simple, highly practiced,
voluntary movements in response to a verbal command
or imitation, and therefore measures verbal comprehen-
sion and motor co-ordination and is used to monitor
changes in cognitive function. The BPT was adminis-
tered by a trained research assistant.
DNA isolation and DNA methylation arrays
Buccal (cheek) swabs were collected from each partici-
pant using standard protocols, and DNA isolated using
the Isohelix Buccal DNA isolation kit (Cell Projects,
Kent, UK) as per manufacturer’s instructions. DNA was
then purified and concentrated using the DNA Clean &
Concentrator kit (Zymo Research, Irvine, CA, USA). Ap-
proximately 750 ng of DNA was used for bisulfite con-
version using the Zymo Research EZ DNA Methylation
Kit (Zymo Research, Irvine, CA, USA). Sample yield and
purity was assessed after each step using a Nanodrop
ND-1000 (Thermo Scientific, Irvine, CA). After bisulfite
conversion, 160 ng of DNA was applied to the Illumina
450 K methylation array, as per manufacturer’s protocols
(Illumina, San Diego, CA, USA).
Data quality control and normalization
Data was subjected to stringent quality control before
being normalized in R [21]. First, probes for which de-
tection p-values were greater that 0.01, probes with
missing beta values, and probes for which less than three
beads contributed to the signal were eliminated in any
sample (a total of 8620). Next, 11,648 probes on the X
or Y chromosome and 65 probes examining single nu-
cleotide polymorphisms were removed from further ana-
lysis. More recent annotation of the Human Methylation
450 k array was used to filter 32,494 probes that are
known to be polymorphic at the CpG, or probes which
have in silico nonspecific binding to the X or Y chromo-
somes [22]. Together, these measures eliminated 52,827
probes, leaving a total of 432,750 probes for further ana-
lysis. Raw data has been deposited in GEO, accession
number GSE50586. Colour correction, background ad-
justment, and quantile normalization were performed
using the lumi R package, and data was normalized
using peak-based correction [23]. ComBat was used to
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relations for two technical replicates were 0.9949 and
0.9939 before ComBat, and 0.9973 and 0.9963 after
ComBat, indicating minimal batch effect, which was
nonetheless corrected.
Principal component analysis
Principal Component Analysis (PCA) decomposes the
measured methylation patterns into a set of linearly in-
dependent principal component (PC) patterns that are
ranked according to how much variance in the data they
explain. The methylation pattern of each probe i across
all samples, xi
→, can be written as xi
→¼ x þ
X
j
aij vj
→ where
x is the mean profile calculated over all the probes in
the dataset. vj
→
are the eigenvectors (PCs), and aij are the
projection values of each probe i onto the eigenvector j.
The top ranked PCs can often be correlated with known
traits in the cohort such as tissue type, cellular compos-
ition, or disease state. Because PCs are linearly inde-
pendent, a particular PC’s contribution to each probe’s
methylation pattern can be subtracted out without alter-
ing the information contained in the pattern arising
from all the others. For this dataset, PCA was performed
on the normalized data set twice; first on the 10 DS and
10 control samples and a second time with ten add-
itional blood samples added. These blood samples were
from unrelated healthy individuals of the same approxi-
mate ages. As described in more detail in the result sec-
tion, the initial PCA without the blood samples revealed
an unusual clustering of samples in the first PC, possibly
indicating blood contamination of the buccal swabs. The
second PCA including blood samples showed that in-
deed, some of our buccal swabs had scores more similar
to blood than other buccal swabs for PC1. Since the de-
pendency of methylation on tissue represented by that
PC1 for this study is a confounder, its contribution to
each probe was subtracted out, yielding methylation data
that no longer has variation due to tissue differences. A
dataset xi
→
were the contribution of PC number k is sub-
tracted out is constructed as xi
→¼ x þ
X
j≠k
aij vj
→
. Our
final data set then had 388,607 probes, since only probes
for which we had data for all samples – the 20 from our
DS/Control study plus the ten blood samples we used to
determine the tissue-related variation in our data. Den-
drograms were generated using Euclidean distance.
Differential methylation analysis
All statistical analysis on normalized and corrected data
was performed using R statistical software (version 3.0).
Probes with DNA methylation levels significantly differ-
ent between DS and control participants were identified
first using the R limma package’s moderated t-tests withempirical Bayesian variance method and Benjamini-
Hochberg correction to control the false discovery rate
at 0.01 [26]. Significant probes were then filtered to in-
clude only those that also had a beta value difference be-
tween DS and control group means (Δbeta) of at least
10%. This cutoff is used to eliminate probes that have
relatively small magnitude of change between groups re-
gardless of their statistical significance. In addition, we
used the “Bump Hunting” method from the R CHARM
package to discover groups of probes that show differen-
tial methylation, and used this list of differentially meth-
ylated regions (DMRs) to identify genes that contain
multiple differentially methylated probes [27].
Correlations between BPT scores in DS participants
and DNA methylation levels both for all probes and for
the APP probes specifically were performed in R using a
2-sided Spearman correlation, and p-values were cor-
rected with Benjamini-Hochberg or Bonferroni correc-
tion, as noted. For whole-genome correlations, probes
were considered significantly correlated with BPT if the
Benjamini-Hochberg corrected p-values were below 0.01
and the range of highest to lowest beta values was
greater than 10%. T-test were performed using the base
t-test function in R [21].
All statistical analysis was performed on transformed
M-values [28]. All values given in figures and the text
are expressed as beta values.
DAVID analysis
Significant probe accession names were input into the
DAVID online GO clustering tool [29]. Only the probes
used in this analysis from the Illumina 450 k Human
Methylation array were used as a background list. Consist-
ent with published approaches, clusters with enrichment
scores greater than 1.3 were considered significant [29].
Results
Participants and brief praxis scores
Scores on the BPT ranged from 35 to 80 for the 10 par-
ticipants with DS, and all 10 control participants re-
ceived a score of 100 (Table 1). Mean age and SD were
matched across groups (means 34.13 for DS and 34.5 for
control, SD 6.12 for DS and 6.78 for control), and a t-
test p-value of 0.90 showed good matching of cohort
ages. Praxis scores were not significantly correlated with
age in the DS cohort (Spearman’s correlation p = 0.55).
Principal component analysis to eliminate sample tissue
variability
Hierarchical clustering of global DNA methylation placed
the 5 DS cases with the higher BPT scores closer to the
controls than participants with lower scores though the
difference in scores between the groups was not statisti-
cally significant (Welsh two sample t test p value = 0.07)
Table 1 Demographics and brief praxis scores of all
participants
Sample ID Sample
group
Sex Age at time
of sampling
Total brief
praxis score
C1 Control F 30.00 100
C2 Control M 28.00 100
C3 Control F 45.00 100
C4 Control M 47.00 100
C5 Control M 33.00 100
C6 Control F 30.00 100
C7 Control F 38.00 100
C8 Control M 30.00 100
C9 Control M 29.00 100
C10 Control F 35.00 100
DS01 DS M 46.56 35
DS02 DS F 38.40 80
DS03 DS F 30.27 80
DS04 DS F 40.68 74
DS05 DS F 35.69 76
DS06 DS M 29.55 70
DS07 DS M 29.52 80
DS08 DS F 30.38 78
DS09 DS M 32.96 64
DS10 DS M 27.29 67
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tween the groups with high and low BPT scores (Welsh
two sample t test p value = 0.55).
Principal component analysis (PCA) was used to de-
termine the sources of variance across all samples and
probes. Initial PCA revealed that the 5 participants with
low BPT scores had markedly different scores for the
first PC, which accounted for 64.8% of the variation,
when compared to controls or the remaining DS partici-
pants (Figure 1b). This amount of variance was unlikely
to be due simply to differences in cognitive impairment,
since previous studies using PCA have generally identi-
fied the first PC as being associated with either tissue
differences or probe-to-probe variation [30,31]. Given
that people with DS are at increased risk of periodontal
disease, we were concerned about blood contamination
in our collected buccal swabs [4]. We added 10 unre-
lated blood samples to our PCA and repeated the ana-
lysis, showing that the new first PC, which had a very
similar shape to the previous first PC, separated tissue
types (Figure 1c). In particular it segregated blood from
buccal samples, with the low BPT scoring DS partici-
pants having intermediate scores. This could indicate
that the different scores in the original PCA between the
low and high BPT were due to the five low BPT buccalswabs having become contaminated with a small amount
of blood. This could be due to the participants having
bitten their cheeks or tongue, or may simply be due to
thinner epithelium and greater probability of periodontal
disease in DS participants [4].
In order to analyze the true differences between the
DS participants and controls, as well as the differences
correlated with BPT, it was important to eliminate this
possible cell type-related confounder. To control for
this, we subtracted from our data set the effects of PC1
from the PCA that included the blood samples (see
Methods). This eliminated the variance due to tissue
contamination while leaving any real DNA methylation
differences between DS and control and any correlations
with cognitive impairment. After subtraction we re-
peated the hierarchical clustering and noted that the dis-
tance between samples was reduced, reflecting the
reduced variation in the modified data set (Figure 1d).
The cluster for the non-contaminated samples changed
as well, likely due to the reduction in variance from all
samples; any variance associated with the blood/buccal
difference would be eliminated, and so the noise that
had been obscuring the true relationship between the
samples was removed. The five low BPT samples now
clustered with one of the other DS samples, which could
be due either to a small remnant of the blood differences
in the data, or a true difference between the groups. The
subtracted data was a significant improvement over the
original. After the PC1 subtraction, the new PC1 ac-
counted for a total of 24.1% of the variance and was
correlated with both DS and BPT score, and PC2, ac-
counting for 11.2% of the variance, was correlated with
DS (Additional file 1: Table S1).
Differential DNA methylation between DS and controls
Using a linear model fitting method, we found 9,982
probes that were significantly different between DS and
control samples after Benjamini-Hochberg correction. We
then calculated the absolute difference between means of
beta values for DS and controls, and refer to it as Δbeta.
Of the 9,982 significant probes, 3300 had a Δbeta of more
than 0.1, meaning that the mean methylation values
between groups are different by more than 10%, which we
refer to as differentially methylated probes (DMPs,
Figure 2a, Additional file 2: Table S2). Of these, 2,190 were
more methylated in DS and 1,110 were more methylated
in controls. DMPs were distributed up to 1 Mb away from
the nearest TSS, though hits with higher Δbeta values
tended to be found closer to TSS sites (Figure 2b). CpG
island distribution was significantly altered from the array
background (chi-square pval < 0.005, Figure 2c), with
high-density CpG islands (HC) depleted and low-density
islands enriched, while IC and ICshore proportions were
similar. Finally, we found no enrichment or depletion for
adc
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Figure 1 Clustering and Principal Component analysis revealed and removed contaminating epigenetic signatures from blood in
buccal swabs. a) Dendrogram of relatedness of overall patterns of DNA methylation in all 20 individuals studied. In all figure parts, colours of
participant codes indicate Praxis scores, as shown in scale in centre. b) PCA plot showing individual participants’ scores for PC1 (x-axis) and PC2
(y-axis) without correction. c) PCA plot showing scores for PC1 and PC2 for individual participants as well as 10 blood samples. Five DS participants
clearly scored intermediate between the other buccal samples and the blood scores for PC1. d) Dendrogram of relatedness of overall patterns of DNA
methylation in all 20 individuals studied after removal of PC1 from c. Overall distances between samples were reduced.
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test p = 0.09).
To determine whether we had multiple hits per gene, we
used the Bump Hunter function in the CHARM R package
to find differentially methylated regions (DMRs) [27]. We
found 495 of our DMPs were also found in Bump Hunter
clusters (BH-DMPs) (Figure 2d, Additional file 3: Table S3).
BH-DMPs tended to be found very close to the TSS
(Figure 2e), and island distribution was also significantly
altered from the array background (chi-square pval < 0.005,
Figure 2f).
Within the DMPs and BH-DMPs, we found a number of
genes known to have functions related to the pathology of
DS. TFAP2B had 26 out of a total of 45 probes on the array
significantly different between DS and control, 13 of which
overlapped with Bump Hunter clusters, and all of which
were more methylated in DS by a range of 10-35%. The
significant probes are located between 1.5 kb upstream of
the TSS to 8 kb downstream. This gene was found in a
GWAS study to be associated with type 2 diabetes, and wasfurther characterized to be involved in glucose uptake and
insulin resistance in adipocytes [32,33]. DLX5 and its near
neighbor DLX6-AS had a total of 42 probes in the DMPs,
with 28 of these in the BH-DMPs. DLX5 and DLX6 have
been identified as being important in neural crest differen-
tiation, including GABAergic neurons of the developing
forebrain and craniofacial development, particularly jaw
development [34,35]. TNXB has 23 probes significantly
different between DS and control, all of which are also
found in the BH-DMPs. This gene is an extracellular matrix
protein responsible for Ehlers-Danos syndrome, which has
been hypothesized to have clinical overlap with DS [36].
Finally, CPT1B with 12 CpGs in the DMP and BH-DMP
lists, is a carnitine palmitoyltransferase specifically expressed
in mitochondria of skeletal muscle and associated with
metabolic syndrome and lipid deposition [37,38]. Reflecting
these interesting hits with clear linkages to the biology of
DS and AD, DAVID analysis of our DMP list showed 17
significant clusters of GO terms (Additional file 4: Table S4).
The top cluster had an enrichment score of 8.05 and was
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Figure 2 Epigenetic signature of T21. a) Heatmap of beta values of probes that were significantly different between DS and control participants
with a difference between the means of the groups >10%, 3300 probes total. Yellow indicates higher methylation, and blue indicates lower methylation.
DS participants are shown in blue, controls in red. b) Scatterplot showing relationship of Δbeta (mean difference in beta value between DS and control
participants, y-axis) and distance to transcriptional start site (TSS, x-axis). Probes in red are significantly differently methylated between DS and control as
in a. c) Breakdown of CpG island type in entire array (left column) and significantly different probes shown in a (right column). d) Heatmap of beta values
of probes from a that also overlap with regions of differential methylation identified using the “Bump Hunter” method, 495 total. e) Scatterplot showing
relationship of Δbeta (mean difference in beta value between DS and control participants, y-axis) and distance to transcriptional start site (TSS, x-axis).
Probes in red are significantly differently methylated between DS and control as in d. f) Breakdown of CpG island type in entire array (left column) and
significantly different probes shown in d (right column).
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score of 3.85 and included terms related to protein phos-
phorylation. The third cluster had a score of 2.46 and was
centered on neural development and differentiation. Our
list of DMPs that overlap with Bump Hunter clusters did
not reveal any significant DAVID enrichment categories.
Specific CpGs correlated with cognitive function
For correlations between BPT scores in DS participants
and DNA methylation, we used two approaches. First, we
correlated the methylation profile of each probe genomewide with BPT scores for DS participants only. A normal
Q-Q plot of correlation coefficients revealed significant
skewing from a normal distribution (Figure 3a). We used
a Benjamini-Hochberg corrected cutoff p-value of 0.01 to
determine significance, and a total of 79 probes met this
criteria. To eliminate probes with very little difference be-
tween the DS participants or between DS and control par-
ticipants, we filtered these for probes where the total
range of methylation exceeded 10% within the DS partici-
pants and which passed a t-test for differences between
DS and control at a p-value of 0.05, for a final total of 4
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Figure 3 DNA methylation sites correlated with cognitive
impairment in DS participants. a) Normal Q-Q plot of Spearman
rho correlation coefficients for all probes. S-shape indicates small tails
on the distribution of coefficients. Black points are non-significant
probes, red points are probes which survive Benjamini-Hochberg
correction for correlation between DNA methylation and BPT in DS
participants. b-e) BPT scores (x-axis) plotted against beta values
(y-axis) for five probes found to be significantly correlated with BPT
in DS participants and significantly different between DS and
controls. Blue points indicate DS participants and red points indicate
controls. b) RND1 c) BICC1 d) KIAA1644 and e) Two probes in TSC2.
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formed the same correlation test on the 3300 DMPs from
the previous section. With the same cutoffs, five probes
were significantly correlated with BPT in DS participants,
of which two had been identified in the first correlation
analysis. Combining these two lists then results in seven
probes that were both correlated with BPT in DS partici-
pants and significantly differently methylated between DS
and control. Two of these were poorly correlated with
BPT when all both DS and control samples were tested,
leaving a total of five hits in four genes (Figure 3b-e,
Additional file 5: Table S5). Two probes are found in a
CpG island in the body of TSC2, which has been shown
to be required for mTOR signaling in the brain, which hasbeen associated with cognitive impairment [39,40]. The
third is located 344 bp upstream of the TSS of RND1, a
Rho GTPase on chromosome 12 that regulates axon ex-
tension in dendritic neurons [41,42]. The final two are lo-
cated 1.1 kb upstream of the TSS of KIAA1644, an
uncharacterized protein on chromosome 22, and one is
26 kb downstream of BICC1, involved in kidney de-
velopment and located on chromosome 10. Since so few
probes were found, functional enrichment analysis was
not possible.
Specific analysis of amyloid precursor protein (APP)
No probes from APP were found to be significantly dif-
ferent between DS and control or correlated with BPT
in the whole-genome analysis. To be sure that significant
correlations were not merely being lost in the multiple
testing correction, we performed a targeted analysis of
the 15 CpGs and one non-CpG site from the array that
localized to the APP gene (Figure 4a). We found that
four CpGs were significantly differently methylated be-
tween DS and control (t-test p-value <0.05), one of which
had less than 5% methylation in all samples, and the
remaining three were all located in intron 1 (Figure 4b).
This finding correlated with previous studies that showed
hypomethylation of the promoter in DS patients [17]. We
also found two CpGs correlated with BPT scores in DS
participants only at a BH corrected p-value of 0.05, lo-
cated on either end of the APP gene (Figure 4c). Both
probes show higher methylation with higher BPT scores,
which is consistent with the model that higher levels of
APP are found in patients with AD, but the magnitude of
difference between individuals is small and thus its bio-
logically significance is unclear.
Discussion and conclusions
Whole genome DNA methylation analysis of trisomies
and cases of age-related cognitive impairment have re-
vealed patterns of changes which appear to be associated
with the etiology of each disease [18-20]. Here we add to
the few studies examining whole-genome epigenetic per-
turbation in trisomies, and additionally show that this
T21-related perturbation can coexist with an epigenetic
signature associated with cognitive impairment. Com-
paring individuals with DS who show behavioural evi-
dence of cognitive impairment to cognitively-normal age
matched controls, we have found 3300 probes whose
DNA methylation level differed by more than 10% be-
tween DS and control, and 5 probes which were corre-
lated with Brief Praxis scores, a measure of cognitive
impairment. Interestingly, however, two of the probes
we found correlated with cognitive impairment in our
DS participants were found in the TSC2 gene, a compo-
nent of the mTOR pathway that has been linked to
Alzheimer’s Disease progression. Neither of these lists
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Figure 4 Targeted analysis of APP. a) Structure of the APP gene showing the locations of the 15 CpGs (numbers) and one CpH (letter A)
analyzed in this study. Exons are shown as black boxes, intronic regions as lines. Grey box indicates position of the CpG island. b) Boxplots of
three probes found to be significantly differently methylated between DS and control. CpG identification number as well as numbered position
from A are indicated. c) Scatterplots of beta values (y-axis) versus Brief Praxis scores (X-axis) for the two probes which are significantly correlated
with BPT. Blue points indicate DS participants and red points indicate controls.
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analysis of the APP gene on chromosome 21 revealed
weak if any evidence for epigenetic impacts on the gene
hypothesized to cause the Alzheimer’s Disease-like phe-
notype often seen in people with DS. Particularly strik-
ing in this study was the fact that we found these
signatures in buccal epithelial cells after correction for
contaminating blood cells, highlighting both the pitfalls
and potential rewards of using these easily-accessible
tissues.
Comparing our results with previous studies examin-
ing DNA methylation in DS samples, we found an overlap
in two of seven genes (TSC2 and DIO3) that are differ-
ently methylated in fetal trisomy 21 skin and muscle, and
five genes (RYK, CASP10, MAP2K6, MSTR1, and RARA)
that are differentially methylated in trisomy 18 skin [19].
In another study using adult samples and parallel mea-
surements of approximately 28,000 probes, 118 probes
were found to be significantly different between the
groups [18]. Interestingly, our data overlaps with 18 of the
specific probes they found to be different in lym-
phocytes, and an additional 14 genes with different
probes (Additional file 6: Table S6). For those probes
which overlapped exactly, the direction of difference
in DNA methylation between DS and control was the
same in both studies [18]. A recent study used re-
duced representation bisulfite sequencing to examineDNA methylation in DS placenta. They found 629
sites in 597 unique genes that were significantly dif-
ferent between DS and control placenta. Of these, 93
genes were also found to differ between DS and con-
trol in our analysis, of which three HOXA2, CPT1B,
and GRM6 were found in all three studies (Additional
file 7: Table S7) [18,20]. These sites must then be-
come differently methylated in people with DS very
early in development, since the placental tissue used
in the latter study is of extraembryonic origin. It is
reassuring that despite using different tissues and
technologies, and considering that all three studies
had relatively small cohorts, similar genes were found
across studies. Also similarly to the two latter studies,
we observed a bias towards hypermethylation in DS
compared to control, with more than 66% of our sig-
nificantly different probes being hypermethylated in
DS [18,20].
Tissue composition differences are a bane of epigenet-
ics studies, and thus it is important to continue to de-
velop methods such as the one presented here to control
for these differences. Signatures of different cell types,
even within a given tissue, can easily mask true differ-
ences between groups [30,43], or, as we have shown,
spuriously contribute to differences which may truly
exist. Given that buccal swabs are a popular choice for
population epigenetic studies because of their ease of
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search community to begin looking for and correcting
these types of differences. A recent study examined buc-
cal and blood whole-genome methylation, and deter-
mined that buccal cells cluster together with many other
tissues, while blood methylation patterns are very dis-
tinct [44]. This makes correcting for potential blood
contamination in buccal swabs especially important,
since blood contamination would have a greater effect
on buccal methylation profiles than other tissues. Our
approach of using principal component analysis allowed
us to robustly remove the variation caused by these tis-
sue differences without removing entire probes or sam-
ples from the analysis. One potential problem is that we
may be removing more variation than is required; if
some true variation has the same projections as the tis-
sue differences, we may be losing it as well. On the other
hand, the current analysis gave very robust and unam-
biguous results after this correction, so any improperly
lost variation would have had a minor contribution to
the results.
The fact that an epigenetic signature that includes
genes with functions related to the biology of DS is
strong support for validity of our approach. The top four
CpG clusters as mentioned in the Results section were
related to diabetes, lipid metabolism, neural crest and
craniofacial development, and connective tissue, all of
which are connected to clinical features of DS. Our
DAVID analysis further supported this, with enrichment
clusters overlapping these functions as well as regulation
of apoptosis and skeletal development. The massive en-
richment for genes involving adhesion in our hit list for
differentially methylated probes is interesting as, while a
single CpG site in the Down Syndrome Cell Adhesion
Molecule (DSCAM) gene is present on our hit list, there
were 106 total adhesion-related genes in our DAVID hit
list. DSCAM has been proposed to contribute to the
congenital heart disease feature of DS, and it is possible
that mis-regulation of a large number of adhesion-
related genes through epigenetic modification may ex-
plain the increased risk in the DS population [45]. It is
also notable that we found probes which differed be-
tween DS and control across all chromosomes. The lack
of enrichment for changes in DNA methylation of
probes on chromosome 21 is perhaps counterintuitive,
despite the fact that it is supported by previous studies
showing similar results [18,19]. It could be anticipated
that having three copies of a chromosome would result
in specific epigenetic modifications to attempt and con-
trol for dosage across the trisomy. Unfortunately the DS
participants in our study were not karyotyped, so that
we do not know the extent of their trisomy 21. Given
the differences observed between DS and control, how-
ever, it is clear that the presence of at least a part of anextra chromosome 21 is capable of causing these genome-
wide epigenetic changes.
Given that only five probes in four genes were found
to be both correlated with BPT scores in DS participants
and different between DS and controls, it is impossible
to assess functional enrichment. Two of these four
genes, however, have known functions in neural develop-
ment or degeneration. RND1 is a Rho GTPas that func-
tions to promote dendritic cell growth and axon guidance,
and loss of RND1 expression suppresses axon formation
in hippocampal neurons [41,42]. We found that methyla-
tion of RND1 was positively correlated with BPT, meaning
that lower levels of DNA methylation were associated with
more severe cognitive impairment. If DNA methylation
suppresses RND1 expression, the opposite pattern might
be expected in DS participants, but without knowing the
mechanistic relationship between RND1 expression and
DNA methylation, it is difficult to interpret. The other
gene, TSC2, had two CpGs in an island that overlaps with
exons 27, 28, and 29 that showed decreasing DNA methy-
lation with cognitive impairment. TSC2 is involved in
mTOR signaling, which regulates levels of tau in mouse
neuronal models, resulting in neuropathological symp-
toms which are alleviated when mTOR signaling is re-
duced [39,40,46,47]. Levels of tuberin protein, the TSC2
gene product, are decreased in brain samples of adult
males with DS and AD-like symptoms, and a mouse
knockdown of Tsc2 showed an increase in tau-positive
axon formation in hippocampal neurons [48,49]. In cancer
cells, demethylation of the promoter of TSC2 was shown
to result in an increase in expression [50]. On the surface,
this methylation data appears conflicting, however the is-
land in which our two target CpGs are found is in the
body of the gene, and island CpGs in gene bodies can be
either positively or negatively correlated with gene expres-
sion [51]. We can therefore hypothesize that decreased
methylation of TSC2 in DS participants is associated with
the decreased protein expression, which results in an in-
creased probability of accumulation of tau through mTOR
regulation, which predisposes these patients to AD-like
disease. Thus RND1 and especially TSC2 are interesting
targets for future studies of epigenetic alterations in cogni-
tive impairment.
Cross-sectional studies such as these are important to
discover associations between DNA methylation and
cognitive impairment. Given our relatively small sample
size, we were surprised to find such clear differences be-
tween our study groups, but in the future, it will be im-
portant to perform larger and more powerful longitudinal
studies on patients with DS and AD to track the dynamics
of DNA methylation changes during cognitive decline.
Post-mortem brain tissue analysis would also shed further
light on the relationship between epigenetics and cognitive
decline in these patients. Together, these data will help
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cognition, whether altered DNA methylation is a predict-
ive factor for cognitive decline, or whether the two pro-
cesses occur simultaneously.
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